Bio Mol

Articles

Human papillomavirus genotype attribution in
invasive cervical cancer: a retrospective cross-sectional
worldwide study
Silvia de Sanjose, Wim G V Quint, Laia Alemany, Daan T Geraets, Jo Ellen Klaustermeier, Belen Lloveras, Sara Tous, Ana Felix,
Luis Eduardo Bravo, Hai-Rim Shin, Carlos S Vallejos, Patricia Alonso de Ruiz, Marcus Aurelho Lima, Nuria Guimera, Omar Clavero, MariaAlejo,
Antonio Llombart-Bosch, Chou Cheng-Yang, Silvio Alejandro Tatti, Elena Kasamatsu, Ermina Iljazovic, Michael Odida, Rodrigo Prado,
Muhieddine Seoud, Magdalena Grce, Alp Usubutun, Asha Jain, Gustavo Adolfo Hernandez Suarez, Luis Estuardo Lombardi, Aekunbiola Banjo,
Clara Menéndez, Efrén Javier Domingo, Julio Velasco, Ashrafun Nessa, Saibua C Bunnag Chichareon, You Lin Qiao, Enrique Lerma,Suzanne M Garland, Toshiyuki Sasagawa, Annabelle Ferrera, Doudja Hammouda, Luciano Mariani, Adela Pelayo, Ivo Steiner, Esther Oliva,
Chris J L M Meijer, Waleed Fahad Al-Jassar, Eugenia Cruz, Thomas C Wright, Ana Puras, Cecilia Ladines Llave, Maria Tzardi, Theodoros Agorastos,
Victoria Garcia-Barriola, Christine Clavel, Jaume Ordi, Miguel Andújar, Xavier Castellsagué, Gloria I Sánchez, AndrzejMarcin Nowakowski,
Jacob Bornstein, Nubia Muñoz, F Xavier Bosch, on behalf of the Retrospective International Survey and HPV Time Trends Study Group

Summary
Lancet Oncol 2010; 11: 1048–56
Published Online
October 18, 2010
DOI:10.1016/S14702045(10)70230-8
See Reflection and Reaction
page 1013
IDIBELL, Institut Català
d’Oncologia-Catalan Institute
of Oncology, L’Hospitalet de
Llobregat,Barcelona, Spain
(S de Sanjose MD, L Alemany MD,
J E Klaustermeier BSc,
B Lloveras MD, S Tous BSc,
N Guimera BSc, O Clavero MD,
M Alejo MD, X Castellsagué MD,
N Muñoz MD, F X Bosch MD);
CIBER en Epidemiología y Salud
Pública, Barcelona, Spain
(S de Sanjose, L Alemany,
J E Klaustermeier, X Castellsagué);
DDL Diagnostic Laboratory,
Voorburg, Netherlands
(W G V Quint PhD,
D T Geraets MSc);Hospital del
Mar, Barcelona, Spain
(B Lloveras); Instituto
Portugues de Oncologia de
Lisboa Francisco Gentil, Lisbon,
Portugal (A Felix MD); Hospital
Universitario del Valle, Cali,
Colombia (L E Bravo MD);
National Cancer Centre, Seoul,
South Korea (H-R Shin MD);
Instituto Nacional de
Enfermedades Neoplásicas,
Lima, Peru (C S Vallejos MD);
Hospital General de México,
Facultad deMedicina,
Universidad Nacional
Autónoma de México, México,
México (Prof P A de Ruiz MD);
Laboratório de Anatomia
Patológica e citologia,
Associação de Combate ao
Câncer do Brasil Central,
Hospital Dr Hélio Angotti,
PATMED, Uberada, Brazil

1048

Background Knowledge about the distribution of human papillomavirus (HPV) genotypes in invasive cervical cancer
is crucial to guide theintroduction of prophylactic vaccines. We aimed to provide novel and comprehensive data about
the worldwide genotype distribution in patients with invasive cervical cancer.
Methods Paraffin-embedded samples of histologically confirmed cases of invasive cervical cancer were collected from
38 countries in Europe, North America, central South America, Africa, Asia, and Oceania. Inclusion criteria were apathological confirmation of a primary invasive cervical cancer of epithelial origin in the tissue sample selected for
analysis of HPV DNA, and information about the year of diagnosis. HPV detection was done by use of PCR with
SPF-10 broad-spectrum primers followed by DNA enzyme immunoassay and genotyping with a reverse hybridisation
line probe assay. Sequence analysis was done to characteriseHPV-positive samples with unknown HPV types. Data
analyses included algorithms of multiple infections to estimate type-specific relative contributions.
Findings 22 661 paraffin-embedded samples were obtained from 14 249 women. 10 575 cases of invasive cervical cancer
were included in the study, and 8977 (85%) of these were positive for HPV DNA. The most common HPV types were
16, 18, 31, 33, 35, 45,...